Appendix A

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Review of TA No. 101; Prostate cancer (hormone-refractory) - docetaxel

Matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturers/sponsors</strong></td>
<td><strong>General</strong></td>
</tr>
<tr>
<td>• Actavis UK (docetaxel)</td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td>• Hospira UK (docetaxel)</td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Medac UK (docetaxel)</td>
<td>• Care Quality Commission</td>
</tr>
<tr>
<td>• Sandoz (docetaxel)</td>
<td>• Commissioning Support Appraisals Service</td>
</tr>
<tr>
<td>• Sanofi (docetaxel)</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Teva UK (docetaxel)</td>
<td>• Healthcare Improvement Scotland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Patient/carer groups</strong></th>
<th><strong>Comparator manufacturers</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Afiya Trust</td>
<td>• Baxter Oncology (mitoxantrone)</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• Hospira UK (mitoxantrone)</td>
</tr>
<tr>
<td>• Bob Champion Cancer Trust</td>
<td>• Pfizer (mitoxantrone)</td>
</tr>
<tr>
<td>• Cancer Black Care</td>
<td>• Sandoz (mitoxantrone)</td>
</tr>
<tr>
<td>• Cancer Equality</td>
<td>• Teva UK (mitoxantrone)</td>
</tr>
<tr>
<td>• Counsel and Care</td>
<td>• Wockhardt UK (mitoxantrone)</td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td><strong>Relevant research groups</strong></td>
</tr>
<tr>
<td>• Everyman</td>
<td>• Cochrane Prostatic Diseases and Urologic Cancers Group</td>
</tr>
<tr>
<td>• Helen Rollason Heal Cancer Charity</td>
<td>• Institute of Cancer Research</td>
</tr>
<tr>
<td>• Macmillan Cancer Support</td>
<td>• MRC Clinical Trials Unit</td>
</tr>
<tr>
<td>• Maggie’s Centres</td>
<td>• National Cancer Research Institute</td>
</tr>
<tr>
<td>• Marie Curie Cancer Care</td>
<td>• National Cancer Research Network</td>
</tr>
<tr>
<td>• Muslim Council of Great Britain</td>
<td>• National Institute of Health Research</td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td><strong>Professional groups</strong></td>
</tr>
<tr>
<td>• Orchid</td>
<td>• Association of Cancer Physicians</td>
</tr>
</tbody>
</table>
| • PCaSO – Prostate Cancer Network | • British Association for Services to the ...
| • Prostate Cancer Charity | **Consultees** |
| • Prostate Help Association | **Commentators (no right to submit or appeal)** |
| • Prostate Cancer Support Federation | **General** |
| • Specialised Healthcare Alliance | • Board of Community Health Councils in Wales |
| • South Asian Health Foundation | • British National Formulary |
| • Sue Ryder Care | • Care Quality Commission |
| • Tenovus | • Commissioning Support Appraisals Service |

National Institute for Health and Clinical Excellence
NICE Technology Appraisal Guidance no. 101; Prostate cancer (hormone-refractory) - docetaxel
Issue date: February 2012
### Consultees

<table>
<thead>
<tr>
<th>Elderly</th>
</tr>
</thead>
<tbody>
<tr>
<td>• British Association of Urological Nurses</td>
</tr>
<tr>
<td>• British Association of Urological Surgeons</td>
</tr>
<tr>
<td>• British Geriatrics Society</td>
</tr>
<tr>
<td>• British Institute of Radiology</td>
</tr>
<tr>
<td>• British Prostate Group</td>
</tr>
<tr>
<td>• British Psychosocial Oncology Society</td>
</tr>
<tr>
<td>• Cancer Network Pharmacists Forum</td>
</tr>
<tr>
<td>• Cancer Research UK</td>
</tr>
<tr>
<td>• Pelican Cancer Foundation</td>
</tr>
<tr>
<td>• Royal College of General Practitioners</td>
</tr>
<tr>
<td>• Royal College of Nursing</td>
</tr>
<tr>
<td>• Royal College of Pathologists</td>
</tr>
<tr>
<td>• Royal College of Physicians</td>
</tr>
<tr>
<td>• Royal College of Radiologists</td>
</tr>
<tr>
<td>• Royal Society of Medicine</td>
</tr>
<tr>
<td>• Society and College of Radiographers</td>
</tr>
<tr>
<td>• United Kingdom Clinical Pharmacy Association</td>
</tr>
<tr>
<td>• United Kingdom Oncology Nursing Society</td>
</tr>
</tbody>
</table>

### Commentators (no right to submit or appeal)

| Ovarian & Prostate Cancer Research Trust |
| Pro-Cancer Research Foundation          |
| Prostate Action (formerly Prostate UK/Prostate Cancer Research Foundation) |
| Research Institute of the Care of Older People |

#### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### Associated Guideline Groups
- National Collaborating Centre for Cancer

#### Associated Public Health Groups
- None

---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**
Appendix A

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.